LGALS3 and neoplasm: These results may explain the “cancer stealth” effects by tumor-secreting Gal-3 or consumption of the inhibitors due to unspecific binding to other Galectins, in which we proposed that a larger dose of specific Gal-3 inhibitor may resolve the clinical dilemma.